The Current Ratio as of September 2024 (TTM) for Keros Therapeutics, Inc. (KROS) is 20.37

According to Keros Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 20.37. This represents a change of 5.01% compared to the average of 19.40 of the last 4 quarters.

Keros Therapeutics, Inc. (KROS) Historical Current Ratio (quarterly & annually)

How has KROS Current Ratio performed in the past?

The mean historical Current Ratio of Keros Therapeutics, Inc. over the last ten years is 15.70. The current 20.37 Current Ratio has changed 12.87% with respect to the historical average. Over the past ten years (40 quarters), KROS's Current Ratio was at its highest in in the December 2020 quarter at 37.27. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Keros Therapeutics, Inc. (KROS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Keros Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Keros Therapeutics, Inc. (KROS) Average Current Ratio

How has KROS Current Ratio performed in the past?

The current Current Ratio of Keros Therapeutics, Inc. (KROS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Keros Therapeutics, Inc. (KROS) Current Ratio vs. Peers

How is KROS’s Current Ratio compared to its peers?

Keros Therapeutics, Inc.’s Current Ratio is greater than IDEAYA Biosciences, Inc. (17.50), greater than AnaptysBio, Inc. (9.09), greater than MeiraGTx Holdings plc (2.36), greater than Homology Medicines, Inc. (4.19), less than Janux Therapeutics, Inc. (57.34), greater than Fennec Pharmaceuticals Inc. (8.02), less than Edgewise Therapeutics, Inc. (30.24), greater than Harmony Biosciences Holdings, Inc. (3.13), greater than Aerovate Therapeutics, Inc. (6.51), greater than Syndax Pharmaceuticals, Inc. (10.50), greater than Mineralys Therapeutics, Inc. (11.20), greater than Replimune Group, Inc. (13.46), greater than Erasca, Inc. (16.79), greater than Century Therapeutics, Inc. (10.62), greater than NGM Biopharmaceuticals, Inc. (7.79), greater than Monte Rosa Therapeutics, Inc. (6.56), greater than Surrozen, Inc. (6.96), greater than Bolt Biotherapeutics, Inc. (4.28), greater than Larimar Therapeutics, Inc. (10.93), greater than Kezar Life Sciences, Inc. (9.58),

Build a custom stock screener for Keros Therapeutics, Inc. (KROS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Keros Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Keros Therapeutics, Inc. (KROS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Keros Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.